The recent $571.5 million licensing agreement between SK Biopharmaceuticals Co., Ltd., and Full-Life Technologies Limited marks a significant milestone in the biotech industry. This exclusive deal grants SK Biopharmaceuticals the rights to develop, manufacture, and commercialize FL-091, an
The global obesity epidemic has led to an urgent demand for innovative and effective treatments. Traditional methods like diet, exercise, and surgical interventions present various challenges, often marked by inconsistent results and reduced patient compliance. In response, the pharmaceutical
Merck has unveiled its first GMP-compliant manufacturing line for cell culture media (CCM) in China. This state-of-the-art facility is located at the Life Science Center in Nantong. The endeavor is backed by a substantial €6.6 million ($7.1 million) investment and aims to meet the burgeoning d
Cardurion Pharmaceuticals has recently made headlines by securing a $260 million Series B financing round. This substantial investment underscores the fierce commitment to advancing the treatment of heart disease, one of the leading causes of mortality worldwide. The funds raised will propel
Rentschler Biopharma, a renowned contract development and manufacturing organization (CDMO), has recently made significant strides in expanding its facilities and operational capabilities. Located in Milford, Massachusetts, the new addition emphasizes the company's dedication to the burgeoning
An exciting development in the biotechnology industry has emerged as 3D Bio-Tissues, a biotech startup supported by BSF Enterprise, has successfully created high-quality lab-grown leather. This remarkable bio-engineered material, which was recently showcased at the Future Fabrics Expo in London,
The biopharmaceutical industry is in the midst of a significant surge, propelled by concerted expansion efforts, substantial financial investments, and strategic alliances. This dynamic landscape is marked by the growing demand for sophisticated therapeutics, which has led companies to bolster
Arbutus Biopharma Corporation (NASDAQ:ABUS) has recently garnered considerable attention in the financial markets, experiencing a significant surge in its stock value. The company's stock recently hit a new 52-week high of $3.65 during mid-day trading on a Friday, ultimately closing at $3.60
The biotech industry in 2024 presents a stark contrast. On one hand, a surge of startups is enjoying robust financial support and offering abundant job opportunities. On the other hand, major established companies are grappling with significant layoffs and restructuring efforts. This juxtaposition
In a groundbreaking partnership aimed at revolutionary advancements in biopharmaceutical research, Pfizer and Evotec have joined forces to discover new therapeutics targeting metabolic and infectious diseases. Announced on July 10, 2024, this collaboration will leverage Evotec’s state-of-the-art r
